Instrument Inactif

Communiqués Celldex Therapeutics, Inc. Deutsche Boerse AG

Actions

US15117B1035

Recherche biotechnologique et médicale

Communiqués

14/06	Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting	AQ
14/06	Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting	AQ
10/06	Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress	AQ
08/05	Celldex Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Celldex: Q1 Earnings Snapshot	AQ
07/05	Celldex Reports First Quarter Financial Results and Provides Corporate Update	AQ
13/04	Celldex to Present at Upcoming Investor Conference	AQ
06/04	Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares	AQ
02/04	Celldex Announces Pricing of $300 Million Public Offering of Common Stock	AQ
01/04	Celldex Announces Proposed Public Offering of Common Stock	AQ
27/03	Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026	AQ
02/03	Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria and Symptomatic Dermographism	AQ
01/03	Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026	AQ
27/02	Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026	AQ
26/02	Celldex Completes Enrollment in Global Phase 3 Studies of Barzolvolimab in Chronic Spontaneous Urticaria	AQ
25/02	Celldex: Q4 Earnings Snapshot	AQ
25/02	Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update	AQ
25/02	Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria	AQ
24/02	Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile	AQ
23/02	Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile	AQ
09/02	Celldex to Present at Upcoming Investor Conferences	AQ
09/12	Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism	AQ
10/11	Celldex: Q3 Earnings Snapshot	AQ
10/11	Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
10/11	Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer	AQ